Recombinant Mouse Csf2rb2 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Mouse Csf2rb2 protein (rFc Tag) (Eg2873)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2873

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Csf2rb2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse Csf2rb2 protein His23-Trp440 (Accession# P26954) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 12984
• Accession: P26954
• PredictedSize: 74.4 kDa
• SDS-PAGE: 73-87 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Colony-stimulating factor 2 receptor subunit beta-2 (Csf2rb2) is the common subunit of the type I cytokine receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5. Mutations in Csf2rb2 are associated with pulmonary alveolar proteinosis. Csf2rb2 also effectively predicted the prognosis of patients with lung adenocarcinoma which could also be a potential target for cancer treatment and prevention.

References:

1.Côrte-Real BF. et al. (2022). Front Immunol. 13:1005965.
2.Papiris SA. et al. (2023). ERJ Open Res. 9(6):00703-2023.
3.Zhu N. et al. (2022). Front Oncol. 12:822849.